Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Living Cell Technologies ( (AU:1AI) ).
Algorae Pharmaceuticals Limited, a company listed on the Australian Securities Exchange (ASX), has announced a proposed issue of up to 60,000,000 performance rights. This move is part of a placement or other type of issue, with the proposed issue date set for October 23, 2025. The issuance of these securities is subject to ASX’s agreement to quote them on a deferred settlement basis, and the company has applied for their quotation under the ASX Listing Rules. This strategic decision could impact the company’s market positioning by potentially increasing its capital and enhancing its financial flexibility.
More about Living Cell Technologies
Average Trading Volume: 10,231,180
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$13.5M
See more data about 1AI stock on TipRanks’ Stock Analysis page.